Dmitry Bichev

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Peter Thuss‐Patience, Albrecht Kretzschmar, Dmitry Bichev et al. · European Journal of Cancer · 2011 · 608 citations

Oncology, Gastrointestinal Oncology, Cancer Management +8

Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy

Sylvie Lorenzen, Peter Thuss‐Patience, Salah‐Eddin Al‐Batran et al. · Annals of Oncology · 2013 · 117 citations

Esophagogastric Adenocarcinoma, Esophageal Cancer, Pathologic Complete Response +7

Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Peter Thuss‐Patience, Ralf‐Dieter Hofheinz, Dirk Arnold et al. · Annals of Oncology · 2012 · 70 citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Medicine +8

Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Peter Thuss‐Patience, Albrecht Kretzschmar, Timo M. Deist et al. · Journal of Clinical Oncology · 2009 · 68 citations

Irinotecan Versus, Oncology, Overall Survival +14

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts

Peter Thuss‐Patience, Albrecht Kretzschmar, Yasemin Doğan et al. · British Journal of Cancer · 2011 · 23 citations · Full text